Celularity (CELU) EBIT Margin Growth (5y) (2025)
Celularity (CELU) EBIT Margin Growth (5y) (2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Celularity | 19.68 Mn | 13.50 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -87,836.00 |
| Sep 30, 2025 | -10,088.00 |